HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $27.
September 20, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharma's stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $27 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiterated 'Buy' rating and maintained price target of $27 by HC Wainwright & Co. indicates a positive outlook for Marinus Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100